Research, PHARMA TECH

New technology advances biopharma chromatography productivity

February 16, 2023

New technology advances
Monoclonal antibody drugs (mAbs) make up more than 50
percent of the biologics on the market today, as well as a
significant number of new drugs in the development pipeline. The value and impact of these therapies has been dramatic.

Spotlight

Embleema

Imagine a world in which everyone can contribute to medical research and create safer, less expensive and faster new treatments. Imagine a tamper-proof, holistic, longitudinal and patient-centric worldwide health record interfacing with patients, physicians, care centers, health authorities and the pharmaceutical industry.

OTHER WHITEPAPERS
news image

3 Pillars to Support a Winning Product Launch

whitePaper | January 18, 2023

The lifetime success of a pharmaceutical product is determined within the first few months following a product launch. Two-thirds of all product launches underperform and the majority of launches fail due to lack.

Read More
news image

Reimagining the pharma landscape with design thinking

whitePaper | July 29, 2021

As pharma companies strive for increased commercial success the customer-centric focus can get lost in the adoption of new commercial endeavours. As a result, many have been looking toward the world of design as a way of enhancing their customer engagement and accelerating their position in the market.

Read More
news image

Three Challenges Facing Study Start Up and the Low-Code Solution

whitePaper | December 22, 2022

The life sciences industry has been exploring ways to accelerate the study start up process for well over a decade. The industry has long understood the value behind faster clinical trials: the sooner clinical trial results can be delivered to agencies, the sooner a new treatment can be available for patients.

Read More
news image

Pharma R And D Review

whitePaper | February 11, 2021

Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.

Read More
news image

BUILDING RESILIENT SUPPLY CHAINS REVITALIZING AMERICAN MANUFACTURING AND FOSTERING BROAD-BASED GROWTH

whitePaper | February 24, 2022

The COVID-19 pandemic and resulting economic dislocation revealed long-standing vulnerabilities in our supply chains. The pandemic’s drastic impacts on demand patterns for a range of medical products including essential medicines wreaked havoc on the U.S. healthcare system.

Read More
news image

BUILDING A TOMORROW-READY LAB

whitePaper | September 8, 2022

Charles Darwin famously said on survival, "It is not the strongest of the species that survives, nor the most intelligent; it is the one most adaptable to change." Resilience has become an essential message in today's post-covid, next-normal world.

Read More

Spotlight

Embleema

Imagine a world in which everyone can contribute to medical research and create safer, less expensive and faster new treatments. Imagine a tamper-proof, holistic, longitudinal and patient-centric worldwide health record interfacing with patients, physicians, care centers, health authorities and the pharmaceutical industry.

Events